TORNALATE
LOE ApproachingNDAINHALATIONAEROSOL, METERED
Approved
Dec 1984
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 17h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TORNALATE is a metered-dose aerosol inhaler approved in 1984 as a small-molecule bronchodilator. The specific indication and mechanism of action are not publicly documented in this dataset. The drug is a legacy respiratory product positioned in a mature, competitive market.
LOE Approaching
Moderate competitive pressure (30/100) signals shrinking commercial opportunity; expect limited headcount expansion and focus on retention over revenue growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
TORNALATE offers limited career growth due to its LOE-approaching status and zero linked job openings. Roles on this product tend to be defensive, focused on maximizing remaining lifecycle value and ensuring compliance rather than driving innovation or market expansion.
Brand ManagerField Sales Representative
Worked on TORNALATE at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.